Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback